Gain Therapeutics, Inc.
GANX· Nasdaq
Released Aug 12, 2025, after the close
10-Q filed Aug 12, 2025, 43 days after period end · 0001558370-25-011220
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $95.10K |
| Net Income | -$5.81M | -$8.14M | -$7.69M | -$5.09M |
| EPS Diluted |
Gain Therapeutics, Inc. · CIK 1819411 · Engraved from SEC EDGAR
| -$0.19 |
| -$0.42 |
| -$0.62 |
| -$0.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.